Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akcea Therapeutics Inc (AKCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,617,074
  • Shares Outstanding, K 89,259
  • Annual Sales, $ 55,210 K
  • Annual Income, $ -109,750 K
  • 36-Month Beta 2.57
  • Price/Sales 25.30
  • Price/Cash Flow N/A
  • Price/Book 9.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.65
  • Number of Estimates 3
  • High Estimate -0.63
  • Low Estimate -0.67
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.27 +16.03%
on 12/26/18
33.98 -13.71%
on 01/10/19
+3.39 (+13.07%)
since 12/21/18
3-Month
20.80 +40.96%
on 10/26/18
34.90 -15.99%
on 12/03/18
+7.23 (+32.73%)
since 10/22/18
52-Week
15.73 +86.40%
on 02/27/18
40.75 -28.05%
on 08/07/18
+10.79 (+58.23%)
since 01/22/18

Most Recent Stories

More News
Pfizer Gets FDA's Priority Review for Rare Disease Candidate

FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

AKCA : 29.32 (-2.46%)
ALNY : 80.66 (-2.96%)
IONS : 57.60 (+0.28%)
PFE : 41.88 (-0.92%)
Consolidated Research: 2018 Summary Expectations for TD Ameritrade Holding, Supernus Pharmaceuticals, Akcea Therapeutics, Dell Technologies, iRobot, and Pegasystems -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TD Ameritrade Holding Corporation...

AMTD : 55.74 (+1.49%)
AKCA : 29.32 (-2.46%)
SUPN : 37.62 (-1.13%)
DVMT : 80.00 (-1.39%)
IRBT : 85.40 (+0.76%)
PEGA : 53.88 (-1.32%)
DVMTV : 38.0800 (-16.22%)
Akcea Announces Upcoming Data Presentations at the 2018 American Society of Hematology Annual Meeting

Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that it will present the long-term analyses of the NEURO-TTR open-label extension study and TEGSEDI's...

AKCA : 29.32 (-2.46%)
IONS : 57.60 (+0.28%)
Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions

Approximately 98% of patients receiving highest dose achieved reductions in Lp(a) levels below the established threshold of risk for CVD events

AKCA : 29.32 (-2.46%)
IONS : 57.60 (+0.28%)
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions

Results to be presented show a significant reduction of Lp(a) levels, favorable safety and tolerability profile

AKCA : 29.32 (-2.46%)
IONS : 57.60 (+0.28%)
Akcea Reports Financial Results and Highlights for Third Quarter 2018

TEGSEDI (inotersen) Approved in United States, European Union & Canada

AKCA : 29.32 (-2.46%)
PTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30, 2018.

PTCT : 29.88 (-9.51%)
AKCA : 29.32 (-2.46%)
Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day

Community focuses on elevating awareness of the burden of FCS and impact on daily living

AKCA : 29.32 (-2.46%)
IONS : 57.60 (+0.28%)
Investor Expectations to Drive Momentum within Adient, BT Group, The Kraft Heinz, Teladoc, Oracle, and Akcea Therapeutics -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Adient PLC (NYSE:ADNT), BT...

BT : 15.51 (+1.31%)
TDOC : 60.48 (-3.05%)
AKCA : 29.32 (-2.46%)
ADNT : 18.14 (-2.73%)
KHC : 47.55 (+0.57%)
ORCL : 49.33 (+0.80%)
Akcea Therapeutics to Hold Third Quarter 2018 Financial Results Webcast

Webcast scheduled for Monday, November 5 at 4:30 p.m. Eastern Time

AKCA : 29.32 (-2.46%)
IONS : 57.60 (+0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AKCA with:

Business Summary

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx...

See More

Key Turning Points

2nd Resistance Point 31.51
1st Resistance Point 30.41
Last Price 29.32
1st Support Level 28.12
2nd Support Level 26.93

See More

52-Week High 40.75
Fibonacci 61.8% 31.19
Last Price 29.32
Fibonacci 50% 28.24
Fibonacci 38.2% 25.29
52-Week Low 15.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar